Life Sciences Archive » April, 2017

Life Sciences - April, 2017

343 articles

• Atty Deception Kills Pharma Whistleblower Suit, Judge Rules
• 10th Circ. Backs Law School Lecture Penalty For Okla. Atty
• Warning Would Have Kept Woman From J&J Talc, Jury Told
• 11th Circ. Backs Georgia 'Pill Mill' Doc's 20-Year Sentence
• Retrophin Waived Privilege Over Atty Docs, Shkreli Says
• 6 Cos. Price IPOs Totaling $1B To Conclude Flurry Of Deals
• Deals Rumor Mill: Paytm, M1, BASF
• Brand Battles: Google, Instagram, Bayer, 'Mad Men'
• 5 Firms Set To Launch May With 6 IPOs Surpassing $1.7B
• New Allergan Fat-Freezing Unit Hit With False Ad Suit
• Senators Revive Bill To Speed Up Generic Drug Approval
• Judge OKs Med Device Injury Claim Under Pa. Tort Law Ruling
• Taxation With Representation: Skadden, Wachtell, Allen
• Galena Biopharma Investor Claims Stock Votes Miscounted
• Why Medical Marijuana Delivery May Soon Be Legal In LA
• Health Hires: 8 Firms Add Health, Life Sciences Experts
• J&J Hit With $20M Pelvic Mesh Verdict In Philly
• Aventis Says K&L Gates Fee Bid Survives High Court Ruling
• The Mediator's Proposal As A Tool For Litigants
• FDA Approves Batten Disease Treatment Priced At $702K
• Investors Want Venture Funds Kept Out Of Theranos Suit
• Generic Drug Patent Cases Fell By One-Third In 2016: Report
• PE-Backed Retailer, UK Biotech Price IPOs Totaling $263M
• NuVasive Denied Stay Of Investor Suit Over Kickback Scheme
• Justices Struggle With BPCIA Enigma
• Co. Selling Adulterated Weight Loss Supplements, Buyers Say
• FDA Nominee Clears Senate Panel Despite Dems' Criticism
• Expectations After The Trump Administration's First 100 Days
• KBL Merger Files $100M IPO To Pursue Health Care Buy
• Boston Hospital Pays $10M To End Research Fraud Probe
• Texas Jury Hits GE For $44M Anesthesia Machine Monopoly
• Texas Sues FDA Over Ban On Import Of Execution Drug
• Medical Experts Call Zimmer MDL Subpoenas Inappropriate
• Amphastar Wants Momenta Drug Standards Info In Patent Suit
• South Korea Fines Novartis $48M Over Bribes To Doctors
• 2nd Circ. Reverses NYU's $3.5M Award In Drug License Spat
• Addressing Personal Jurisdiction Limits At The High Court
• UK Product Liability Law Moves Toward US Norms
• Fraudster In $172M Scheme Seeks A Light Sentence
• Bayer Fights En Banc Review Of Dow's $455M Patent Loss
• Pharmacies' Price-Fixing Actions Too Similar, Judge Says
• Propel Loses Quick Win Bids In Dental Device False Ad Row
• Lensar Secures Ch. 11 Plan OK, Lender Debt-To-Equity Deal
• Duke Can't Drop Whistleblower's False Research Data Suit
• Par Hit With Fees For 'Unsupported' Luitpold Patent Suit
• Feds, Ex-MLB Star Clash Over Insider Trading Jury Instructions
• Shkreli Lobs Password-Cracking Allegation At Retrophin
• Halt Medical Bid Protections Are Unnecessary, Trustee Says
• Thinking Fast And Slow About Class Action Reform
• 'Milking' The 1st Amendment To Defend Food Label Claims
• Allergan Settles Apotex Pinkeye Meds Product-Hopping Suit
• DNA Co. Beats Baby Gender Test Suit, For Now
• FINRA, DTC Want Suit Over Bankruptcy Distribution Killed
• Bankrupt Unilife Seeks $1M In Bonuses For Top Brass
• Justices Mull Biosimilar Duties At Amgen-Sandoz Arguments
• The 9-Year Winning Streak Of Virginia 'Rocket Docket'
• Jury Hits Cardio Device Maker With $25M Retaliation Verdict
• GSK Trial Shows Jury's New Role In Drug Labeling Cases
• FDA Warning Wire: Teva, Inspection Refusal, Cheese Deaths
• Medtox Fax Recipients Certified In Revived TCPA Suit
• Calif. Appeals Court Won't Revive Fosamax Suit
• Fed. Circ. Mostly Affirms PTAB In Duke Patent Dispute
• Ex-Hunton Atty Seeks Retrial After Insider Trading Conviction
• Oxygen Equipment Provider To Pay $11.4M To End FCA Suit
• Murder Trial For Pharmacist In Meningitis Outbreak Delayed
• Biotech Investors Seek Ruling On Jefferies Arbitration Fight
• Vagina Reshaping Patent Survives Invalidity Challenge
• Drug Co. Asks Justices To Limit Out-Of-State Tort Claims
• Merck Settles Keytruda Patent Suit For $19.5M
• Scott Gottlieb And The Future Of The FDA
• Let's Talk About Half-Hearted Innovation
• Merck Loses Rehearing Bid In 3rd Circ. Fosamax Warning Suit
• J&J's Talc Caused Woman's Cancer, Harvard MD Tells Jury
• Anthem, Express Scripts To Cut Ties Amid Pricing Fight
• Allen & Overy, Cravath Guide $4.3B Fresenius-Akorn Combo
• Pharmacy Says Aetna Owes $533K For Hemophilia Drugs
• Mylan Rebates Doomed EpiPen Rival, Sanofi Says
• Adderall Generic Blocked After Shire, Amerigen Settle
• 10 Tips For Creating Winning Trial Visuals
• 9th Circ. Says Class Can't Demand Proof In False Ad Row
• 5 Cos. Launch IPOs Surpassing $1.8B As Deals Accelerate
• Judge Keeps Fraud Claims Against GSK Alive In Zofran MDL
• Lilly Hit With $20M Jury Verdict In Cialis Patent Row
• Judge Says Clinics In Meningitis Outbreak Can Blame FDA
• Ex-Disney Workers' ERISA Suit Over Valeant Shares Gets Boot
• Deals Rumor Mill: Hypermarcas, Whole Foods, Abraaj Group
• Vitamin C Antitrust Case Could Trip Trump Up On Trade
• NuVasive Investors Slam Bid To Pause Kickback Class Action
• Test Maker Denies Eavesdropping On Abbott Suit Depos
• Plaintiffs Bar Perspective: Grant & Eisenhofer's Beth Graham
• Counsel To Counsel: Insights From Law Firm GCs
• Skadden, Wachtell Guide $24B Medical Supply Co. Deal
• Medtronic's $17M Patent Infringement Penalty Is Enhanced
• FDA Deluged With Feedback On Off-Label Policies
• No Doubt Talc Can Enter Body, Jury Told In J&J Cancer Trial
• Taxation With Representation: Skadden, Cravath, Simpson
• GSK's Paxil Loss Forces 7th Circ. Generic Liability Showdown
• More Details Out In Del. Bid To Stop Theranos Share Swap
• Meet The Attys Arguing Supreme Court Biosimilars Battle
• 5 Social Media Pitfalls In The Pharmaceutical Industry
• Pa. Mesh Cases Won't Be Stayed For Jurisdiction Appeals
• Honigman Miller Adds Ex-Kirkland & Ellis IP Atty In Chicago
• Tips For Finding Your Company's Hidden IP
• Gray Matters: The Attorney-Client Team
• Cherokees Say Wal-Mart, Walgreens Let Opioids Loose
• Stryker Cut From Zimmer's Howmedica Trade Secrets Suit
• Momenta, Sandoz Again Try To Nix Amphastar's Antitrust Suit
• FDA Warns That Kids Shouldn't Use Codeine, Tramadol
• Why Oregon Lawmakers Are Shielding Cannabis Buyers' Data
• What Current Legal Developments Mean For Biosimilars
• Walking The Lone Pine Trail
• Litigation Finance, Big Data And The Limits Of AI
• Counsel To Counsel: Mama Said There'll Be Days Like This
• Cornell, Illumina Settle Long-Running DNA Analysis IP Suit
• GSK Hit With $3M Verdict For Reed Smith Atty's Suicide
• Bayer Gets Quick Win In Suit Challenging Probiotic Claims
• Pfizer Hit With DOJ Subpoena Over Saline Shortages
• Diabetes Test Maker Eavesdropped In Abbott Suit, Attys Say
• Invisalign Patents To Get Yet Another Look At USPTO
• Indirect Share Purchasers Cleared To Sue Theranos
• Calif. Court Finds Plaintiff 'Vexatious' In GE Med Mal Suit
• 2nd Circ. Judge Rips NY Court's 'Crystal Clear Mistake'
• BioScrip Investors Lose Suit After Targeting Different Board
• Gilead's Unapproved Drug Plant Flouted FCA, 9th Circ. Told
• UK Biotech, Chinese Manufacturer Prime IPOs Totaling $82M
• What Companies Can Expect From The New FDA
• Shkreli, Ex-Katten Atty Get Fraud Trials Severed
• Fresenius, Dialysis Patients Spar Over Documents In MDL
• Female, Male Sexual Enhancement Supplements Recalled
• 4 Consumers Drop Abbott Depakote Birth Defect Suits
• Rutgers' BioArray Licensing Suit Kicked Back To State Court
• Is Multidistrict Litigation In Need Of Reform?
• Shire Files Infringement Suit On Same Day It Gets Drug Patent
• Plaintiffs Bar Perspective: Robbins Geller's Tor Gronborg
• An Earth Day Review Of 'Green Guide' False Advertising
• The ITC's Potential Role In Hatch-Waxman Litigation
• Why P&C Carriers Must Prepare For The Marijuana Market
• Counsel To Counsel: A Law Firm GC's Data Protection Duties
• SAC Capital Blasts Elan Investor's Award Bid In $135M Deal
• Ill. Pharmacy Hits Medical Supply Co. With TCPA Fax Suit
• 'Right To Try' Unapproved Drug Measure Passes Pa. House
• FDA Warning Wire: Faulty St. Jude Devices Used In Patients
• Czech Republic Presses DC Court To Nix $325M Award Suit
• Ariz. AG Gets $4.65M Settlement Over Theranos Blood Tests
• AstraZeneca Can't Shed FCA Suit Over Seroquel 'Scheme'
• Ex-MLB Player Says Limit Insider Trading Trial Instruction
• Medtronics Inks $6.1B Unit Sale To Cardinal Health
• NuVasive Seeks Stay In Investor Suit Amid Class Cert. Appeal
• Counsel To Counsel: Evaluating Positional Conflicts
• Divided Infringement After Eli Lilly V. Teva
• Applying Buckman Preemption To Antitrust And RICO Claims
• Widow's Trial Against GSK Wraps With $39M Damages Plea
• Calif. Says Boehringer Ingelheim Paid Barr $120M For Delay
• Theranos To Stay Out Of Lab Biz In Deal With CMS
• Miss. Sues Drug Cos. Over Medicaid Reimbursements
• Cravath Guides Ashland In $660M Pharmachem Deal
• NJ Tax Court Upholds $5M In Rite Aid Property Assessments
• 7 Cos. Launch IPOs Totaling $967M As Momentum Builds
• Pa. Judge Axes Latest Risperdal Breast-Growth Case Mid-Trial
• Toshiba Medical Settles MRI Patent Suit With NeuroGrafix
• Counsel To Counsel: 5 Challenges For A Law Firm GC
• Tracing The Path To Health Care Investigation Settlements
• Court Orders Document Production In Pharmacy Price Row
• Abbott Says Consumers Are Twisting Law In Depakote Suits
• Venable Cleared To Rep Supplement Co. In False Ad Suit
• SBA To Revise Small Biz Size Standards For Some Industries
• Drug Co. Investors Seek OK For Early $3.8M Settlement
• NECC Owner Says FDA Fraud Is 'Legal Impossibility'
• Biotech Investors Fortify Jefferies Arbitration Battle
• Riverside Collects $418M For Latest Investment Vehicle
• FDA Wants Answers From Abbott On St. Jude Device Security
• Teva Gets Quick Win In IUD Defect Suit
• Cordis Can't Bring Defect Suits To Fed. Court: 9th Circ.
• Chamberlain Hrdlicka Nabs Osha Liang IP Atty In Houston
• Lion Biotech Investors Sue Co. In Wake Of SEC Crackdown
• Ex-Marketing Head Hits Meda Pharmaceuticals With Bias Suit
• Drug Co. Hires Ex-SDNY Brass To Fight $181M Forfeiture
• Baxter Hit With DOJ Subpoena Over Saline Shortages
• Deals Rumor Mill: Toshiba, Verizon, Chiltern International
• Abbott, Alere Drop Court Battle For Smaller $5.3B Merger
• Judge Denies Quick Wins In Lannett CEO's Tax Penalty Suit
• Lawyers In Flow: Get Out Of Your Head And Into Your Case
• Taxation With Representation: Kirkland, Shearman, Davis
• Janssen, Bayer Lose Preemption Bids As Xarelto Trial Nears
• Patient Wants Atty Fee Nixed From DePuy Implant Settlement
• Judge Scolds Unilife DIP Lender For Unjustified Limits
• Berkeley Appeals PTAB Ruling In MIT, Broad CRISPR Dispute
• Judge Nixes Two Experts In NJ Accutane Litigation
• Halt Medical Gets DIP OK To Cover Payroll, Other Expenses
• False Ad Deal With Remedies Co. Gets Nod 2nd Time Around
• 4 Companies Price IPOs Totaling $668M To Cap Busy Week
• 3rd Circ. Will Decide Lipitor, Effexor Pay-For-Delay Suits
• Janssen, Bayer Call Xarelto MDL Exclusion Request Too Broad
• Purchasers Seek Namenda Litigation Docs In Antitrust Suit
• Pfizer Can't Shake Off-Label Marketing FCA Suit
• Halt Medical Files For Ch. 11 Amid Lawsuit Against Lenders
• Roxane Could Owe $2M After Patent Row Ruled 'Exceptional'
• 11th Circ. Denies Doc Stay To Appeal Libel Suit To Justices
• Fed. Circ. Tosses Patent Case Over Nobel-Winning Discovery
• Medical Device Maker Hits Rival With Trade Secrets Suit
• Fed. Circ. Upholds PTAB's Ax Of Novartis MS Drug Patent
• $454M Gown Verdict Says Jury Can Be Swayed Without Harm
• Jury Awards $12.2M To Surgery Tube Co. In False Ad Row
• Stakeholders Must Stay Aware Of E-Cigarette Science
• Spotlight On Corruption-Related Successor Liability Risks
• Generic Nucynta Officially Barred After Depomed Patent Win
• Allergan, Kissei Settle With Sandoz In Prostate Drug Suit
• Alere Escapes Lawsuit Alleging Blood-Testing Errors
• Boehringer Asks DC Circ. To Stay Aggrenox Doc Production
• Depakote Birth Defect Suits Lose Claims Over Repose Limit
• Medical Device E-Commerce Co. Faces TCPA Suit Over Faxes
• Shire Blasts Allergan's Discovery Bid In Antitrust Suit
• Tokai Shareholders File Suit To Stop Otic Pharma Deal
• Injectable Drug System Maker Unilife Hits Ch. 11 In Del.
• A Law Firm Ranking Model By 'Fake News & Distorted Reports'
• Plaintiffs Bar Perspective: Cohen Milstein's Betsy Miller
• Client Conflict Troubled Late Atty, Ex-Colleague Testifies
• J&J Hid Talc Cancer Risk For Profit, Jury Told
• Shire, Actavis Say Intuniv Settlement Not Reverse Payment
• FDA Warning Wire: Mylan's New Woes, NYC Juice Claims
• Guilty Drug Return Co. Should Forfeit $181M, Feds Say
• Bristol-Myers, Pfizer Sue To Halt Generic Blood Thinner
• HGH Supplement Co. Says False Ad Suit Lacks Evidence
• Natural Gas Co., Biotech Firm File IPOs Totaling $586M
• Pharmacist Seeks New Trial On Racketeering Conviction
• Vitamin Health's False Ad Fight Not Covered, 6th Circ. Says
• Metal In Brain Counts As Injury, Patients Tell 11th Circ.
• J&J, Bayer Seek 3rd-Party Funding Info In Pa. Xarelto Cases
• Liberty Tells 10th Circ. MusclePharm's $3M Claim Not Covered
• The 11th Circ.'s Unfortunate Do-Over Christiansen Verdict
• Bellwethers Chosen In 3M Warming Device Infection MDL
• Abbott Admitted To Depakote Mislabeling, Court Told
• Ex-Roche Worker Sues Insurer Over $1.6M Malpractice Ruling
• Roca Can't Unfreeze Assets To Pay Legal Fees, Judge Says
• Shire Scorches FTC Suit Over Anti-Generic Petitions
• Hi-Tech Wins Attys' Fees For ThermoLife 'Nuisance' IP Suit
• 5 Cos. Expand IPO Pipeline With New Filings Exceeding $400M
• Actavis, Taro, Teva Fixed Skin Steroid Price, Suit Says
• Aurobindo Fights To Lift Ban On Biopsy Dye In Mylan Row
• Pharmaceutical Co. Gets Quick Win in PCB Contamination Suit
• Kirkland Steers Bain, Cinven In $5.6B German Pharma Co. Buy
• Inside Trader Says SEC Wants Too-Harsh $2.2M Judgment
• Two IP Attorneys Join Armstrong Teasdale In Kansas City
• Boehringer, Sanofi Must Divest To Clear $24B Deal In Mexico
• Schiff Hardin In Chicago Gains Ex-Duane Morris IP Head
• J&J Unit Asks Judge To Toss Whistleblower's Retaliation Case
• Fed. Circ. Affirms Takeda Loss In Prevacid Patent Case
• 7th Circ. Won't Revisit Eyedrop Suit Against Merck, Others
• How New Expert Witness Rules May Impact Missouri Courts
• Jury Hits Kimberly-Clark, Halyard With $454M Fraud Verdict
• Theranos Investors Can't Delay Class Action-Ending Deal
• 5 Firms To Steer IPOs Totaling $782M As Deals Gather Steam
• Shkreli, Ex-Katten Atty Warn Of Joint Trial Disarray
• JPML Sends Generic Drug Price-Fixing Suits To Pennsylvania
• GlaxoSmithKline Asks Justices To Rule On Paxil Jurisdiction
• Amneal Infringed Truvada Patents, Gilead Says
• Bellwether Trial Dates Set In Meningitis MDL
• Teva, Others Must Face Blood Pressure Drug Antitrust Suit
• Health Hires: Vt. SG To Stris, BCBS In-House To Kilpatrick
• Investors Sue AbbVie Over $1.6B Fee, Say More Loss Looms
• New Strategies For Licensing Of Multicomponent Inventions
• Crowdfunding For Legal Cases: 5 Trends Reshaping Justice
• Gov't Fights Over Facts In Ex-MLB Insider Trading Trial
• Chinese Investor Drops $1.4B For German Drugmaker
• McDermott Nabs Litigation Partner In Dallas From DLA Piper
• Supplement Co. Says Science Backs Up Its Memory Booster
• GSK Doc Says FDA Knew All Co. Did About Paxil Suicide Risk
• Celebrex Buyers Seek Class Cert. In Pfizer Antitrust Suit
• Mylan, Sandoz, Taro Accused Of Fixing OCD Drug Price
• Special Master Appointed In Depakote Trial
• Merck Wants 3rd Circ. Rethink On Fosamax Warning Claims
• Fed. Circ. Rules Mylan Doesn't Infringe Angiomax Patents
• Supplement Co. Fired Staff Over Lawsuit Fears: NLRB Judge
• Ill. City Latest To Sue Mallinckrodt In Antitrust Row
• Amphastar, Momenta Antitrust Dispute Gets 2019 Trial Date
• FDA Backs 23andMe Tests For Parkinson's, Alzheimer's Risks
• Drugmakers Face Antitrust Class Action Over Diabetes Drug
• Investor Suits Against Teva Combined, Moved To Conn.
• Agreement Via Email To End IP Row Is Valid, Judge Says
• ABA Needs A New Model Legal Ethics Rule
• What Does Lateral Partner Success Look Like?
• Kimberly-Clark Gown Buyers Didn't Pay A Premium, Jury Told
• Over FTC Protest, Lidoderm Pay-For-Delay Suit Stayed
• Gorsuch, Roe And 'Superprecedent'
• 5 Takeaways As Trump's FDA Pick Hits Capitol Hill
• Ex-MLB Player Seeks Acquittal On Insider Trading Charges
• Sanofi To Pay $19.8M To Settle VA's Overcharge Claims
• Alere Presses Del. Court For Access To Abbott Atty Docs
• Venable Gets Digital Health, Privacy Pro From Cooley
• Walgreens Hit With False Ad, IP Suit Over Eyelid Scrub
• Medical Co. Founder's Widow Accuses NJ Atty Of Malpractice
• Medtronic Says Some Ventilators Can Reset Without Warning
• Are Lateral Recruitment Opportunities Shaping Your Strategy?
• 2 Plead Not Guilty In Pharmaceutical Insider Trading Scheme
• Xtant Shareholder Demands Books And Records
• J&J, Mesh Patient End Texas High Court Appeal
• The Trump Administration's Views On Marijuana Enforcement
• Devil Is In The Detail: Lessons On Drafting Earnouts
• Sandoz, Lupin To Pay Combined $6.7M In Pay-For-Delay MDL
• NJ Pharma Co. Hits Manufacturer With €3M Commissions Suit
• Xencor Recap Settlement's $2.4M Balance Approved In Del.
• Express Scripts Concealing Basic Pricing Info, Anthem Says
• Fed. Circ. Backs $6M Fee Award For Medtronic In Patent Case
• FDA Warning Wire: Agency Skeptical Of Cannabis Oil Claims
• Vitamin C Buyers Ask Supreme Court To Revive Antitrust Suit
• Biogen Accused Of Stifling Neurological Drug Competition
• Lateral Partner Hiring: Time To Look In The Mirror
• Swiss-American Must Face False Sunscreen SPF Class Action
• GSK Can't Score Early Win In Atty Suicide Trial
• Gov't Says Ex-MLBer Can't Admit 'Sloppy' Notes In Trial
• Pa. Appeals Court Won't Revive Liquisolid Licensing Row
• KKR-Backed REIT, British Biotech Join Growing IPO Pipeline
• Fed. Circ. Affirms Nix Of Novartis Dementia Patch Patents
• Ex-NFLer Fights SEC's Negligence Verdict At 9th Circ.
• McKesson Investor Sues Board After $150M DOJ Fine
• Mintz Levin Nabs Ex-Kilpatrick Townsend Patent Partner
• Investors Push For FINRA Arbitration In Battle With Jefferies
• Biotech CEO Dodges Prison For False SEC Filings
• Printing Co. CEO Admits To Trafficking Fake Vet Med Labels
• Kimberly-Clark Gowns Should Have Been Recalled, Jury Told
• 6 More Sentenced In Fla. For $172M Insurance Fraud
• Fla. Senate Panel Expands Medical Marijuana Bill
• Atty Wasn't Driven To Suicide By Work: Reed Smith Partner
• Allergan Must Face FCA Suit Over Drug Samples, Rx Pads
• PTAB Invalidates Patent For Hypertension Treatment
• FCA Decision Tracker: Continued Interpretations Of Escobar
• Patients Ask 5th Circ. To Restore $502M J&J Hip Verdict
• Krill Oil Cos. Reach $1.6M Deal To End Patent Dispute
• BCBS Gets Heart Device Co.'s $66.5M Antitrust Suit Tossed
• Dow Wants Review Of $455M Weed Control Patent Loss
• New Philly Jury Begins 7th Risperdal Trial
• NY Goes After MedImmune In Kickback Scheme Suit
• Recall Of Potentially Faulty EpiPens Widens
• Impax, AstraZeneca Get Win In Generic Zomig Patent Case
• PE-Backed Met Coal Co. Leads 3 IPO Launches Totaling $530M
• Novartis' Hep C Patents Invalid Under Alice, AbbVie Says
• PTAB Allows Shire To Amend Adderall Patent In AIA Review
• Justices Won't Hear Reglan Failure-To-Warn Appeal
• 6 Cos. Expand Growing IPO Pipeline With New Filings
• Enzymotec Settles IPO Stock-Drop Suit For $6.5M
• Tibet Pharmaceuticals Exec Escapes Class Action Over IPO
• Four Firms Guide Apax Partners' $397M Deal For Syneron
• Another Step Toward Reasonable Preemption Case Law